DelveInsight’s, “Nasopharyngeal Cancer Pipeline Insight 2023” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the Nasopharyngeal Cancer pipeline landscape. It covers the Nasopharyngeal Cancer pipeline drug profiles, including Nasopharyngeal Cancer clinical trials and nonclinical stage products. It also covers the Nasopharyngeal Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For the Nasopharyngeal Cancer emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). It provides a detailed description of each drug, including its mechanism of action, Nasopharyngeal Cancer clinical trial studies conducted for Nasopharyngeal Cancer, any NDA approvals obtained for Nasopharyngeal Cancer, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.
To explore more information on the latest breakthroughs in the Nasopharyngeal Cancer Pipeline treatment landscape of the report, click here @ Nasopharyngeal Cancer Pipeline Outlook
Key Takeaways from the Nasopharyngeal Cancer Pipeline Report
- DelveInsight’s Nasopharyngeal Cancer Pipeline analysis depicts a robust space with 30+ active players working to develop 30+ pipeline treatment therapies.
- The leading Nasopharyngeal Cancer Companies are working in the market include Novartis Pharmaceuticals, innovent Biologics, BeiGene, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme Corp., Tessa Therapeutics, Akeso Pharmaceuticals, Inc., Jiangsu HengRui Medicine Co., Ltd., Atara biotherapeutics, Incyte Corporation, Bristol-Myers Squibb, Hoffman La Roche, Betta Pharmaceuticals Co., Ltd., Hoffman La Roche, Klus Pharma, and others
- Emerging Nasopharyngeal Cancer Pipeline Therapies in the various stages of development include Auto-Dendritic Adjuvant Therapy, Oxaliplatin, capecitabine [Xeloda], Capecitabine, Cisplatin, TQB2858 Injection, Anlotinib Hydrochloride Capsule, Gemcitabine hydrochloride injection, Tislelizumab, SHR-1210, Zometa (zoledronic acid), AK105, Camrelizumab, and others
- On September, 2022, PT. Prodia Stem Cell Indonesia has announced drug named Auto-Dendritic Adjuvant Therapy in the market with the phase 1 and 2. The purpose of this study is to determine the safety and potential of dendritic cells therapy and secretomes therapy for advanced nasopharyngeal cancer.
- On January, 2022, Chia Tai Tianqing Pharmaceutical Group Co., Ltd has announced drug named TQB2858 Injection, Anlotinib Hydrochloride Capsule, Gemcitabine hydrochloride injection, Cisplatin Injection in the market of phase 1 and 2. This study is a single-arm, randomized, open-label, multi-cohort Phase Ib clinical trial. The experimental drug is TQB2858 Injection. The trial was divided into 3 cohorts. Cohort 1 included patients with advanced nasopharyngeal carcinoma who had previously failed platinum-based chemotherapy and immune checkpoint inhibitors (programmed cell death protein 1 (PD-1)/ Programmed death-ligand 1 (PD-L1), etc.). Cohorts 2 and 3 were randomized into patients with advanced, untreated nasopharyngeal carcinoma who had not received prior systemic therapy. A total of 60-90 subjects are required.
Nasopharyngeal Cancer Overview
Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the nasopharynx, the upper part of the throat behind the nose and near the base of skull. In early cases Nasopharyngeal cancer may not cause any symptoms. The possible symptoms may include: lump in neck, blood in saliva, frequent ear infections, sore throat, nasal congestion, hearing loss.
For further information, refer to the detailed Nasopharyngeal Cancer Unmet Needs, Nasopharyngeal Cancer Market Drivers, and Market Barriers, click here for Nasopharyngeal Cancer Ongoing Clinical Trial Analysis
Nasopharyngeal Cancer Emerging Drugs Profile
- Sintililimab: Innovent Biologics (Suzhou) Co. Ltd.
- Tislelizumab: BioGene
- Tabelecleucel: Atara Biotherapeutics Inc.
- PDR001: Novartis Pharmaceuticals
Nasopharyngeal Cancer Pipeline Therapeutics Assessment
There are approx. 10+ Nasopharyngeal Cancer companies which are developing the therapies for Nasopharyngeal Cancer. The Nasopharyngeal Cancer companies which have their Nasopharyngeal Cancer drug candidates in the most advanced stage, i.e. phase III include, Innovent Biologics.
Request a sample and discover the recent advances in Nasopharyngeal Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Nasopharyngeal Cancer Treatment Landscape
Nasopharyngeal Cancer Therapeutics Assessment
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Nasopharyngeal Cancer Therapeutics Market include-
Novartis Pharmaceuticals, innovent Biologics, BeiGene, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme Corp., Tessa Therapeutics, Akeso Pharmaceuticals, Inc., Jiangsu HengRui Medicine Co., Ltd., Atara biotherapeutics, Incyte Corporation, Bristol-Myers Squibb, Hoffman La Roche, Betta Pharmaceuticals Co., Ltd., Hoffman La Roche, Klus Pharma, and others
Dive deep into rich insights for drugs for Nasopharyngeal Cancer Pipeline, click here @ Nasopharyngeal Cancer Unmet Needs and Analyst Views
Scope of the Nasopharyngeal Cancer Pipeline Report
- Coverage- Global
- Nasopharyngeal Cancer Companies- Novartis Pharmaceuticals, innovent Biologics, BeiGene, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme Corp., Tessa Therapeutics, Akeso Pharmaceuticals, Inc., Jiangsu HengRui Medicine Co., Ltd., Atara biotherapeutics, Incyte Corporation, Bristol-Myers Squibb, Hoffman La Roche, Betta Pharmaceuticals Co., Ltd., Hoffman La Roche, Klus Pharma, and others
- Nasopharyngeal Cancer Therapies- Auto-Dendritic Adjuvant Therapy, Oxaliplatin, capecitabine [Xeloda], Capecitabine, Cisplatin, TQB2858 Injection, Anlotinib Hydrochloride Capsule, Gemcitabine hydrochloride injection, Tislelizumab, SHR-1210, Zometa (zoledronic acid), AK105, Camrelizumab, and others
- Nasopharyngeal Cancer Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Nasopharyngeal Cancer Merger and acquisitions, Nasopharyngeal Cancer Licensing Activities @ Nasopharyngeal Cancer Emerging Drugs, and Recent Trends
Table of Content
- Introduction
- Nasopharyngeal Cancer Executive Summary
- Nasopharyngeal Cancer: Overview
- Nasopharyngeal Cancer Pipeline Therapeutics
- Nasopharyngeal Cancer Therapeutic Assessment
- Nasopharyngeal Cancer – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Nasopharyngeal Cancer Collaboration Deals
- Late Stage Products (Phase III)
- Sintililimab: Innovent Biologics (Suzhou) Co. Ltd.
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- PDR001: Novartis Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- SHR-1701: Jiangsu Hengrui Medicine Co.
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Drug Name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Nasopharyngeal Cancer Key Companies
- Nasopharyngeal Cancer Key Products
- Nasopharyngeal Cancer - Unmet Needs
- Nasopharyngeal Cancer - Market Drivers and Barriers
- Nasopharyngeal Cancer - Future Perspectives and Conclusion
- Nasopharyngeal Cancer Analyst Views
- Nasopharyngeal Cancer Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/conference-coverage-car-tcr-summit
